Niche oncology focus Perseus PCI positioning around an alternative cancer treatment with reduced side effects could be a compelling entry point for oncology clinics, holistic care providers, and integrative medicine centers seeking non-chemotherapy options for patients.

FDA trial status The treatment has safety and effectiveness proven in US FDA sanctioned trials, with ongoing US approval and manufacturing/administration approval already secured in the Cayman Islands, presenting a need to engage regulatory consultants, CROs, and trial support services for potential US pathway acceleration.

Limited scale With a small team (2-10 employees) and revenue under one million, Perseus PCI may require partnerships or managed service arrangements with experienced healthcare sales, clinic networks, and outsourcing providers to scale outreach, deployment, and post-treatment support.

Tech stack leverage Existing technology footprint (WordPress, Google tags, analytics, and video hosting) suggests opportunities to augment marketing attribution, optimize lead capture from medical professionals, and integrate secure patient engagement workflows through trusted platforms.

Strategic partnerships The company’s niche in a high-stakes medical area opens doors for collaborations with medical groups, trial coordinators, and compliance-focused security firms (given the healthcare context and reference to security-grade vendors in similar company profiles) to accelerate market access and trust building.